Stocks:
5,168
ETFs:
2,288
Exchanges:
11
Market Cap:
$63.92T
24h Vol:
$4.36B
Dominance:
MSFT:4.92%
Stocklytics Platform
Instrument logo  APLT
Applied Therapeutics Inc
APLT
60 / 100
High Growth
$5.14arrow_drop_down3.74%-$0.20

Performance History

Stocklytics logo
Key Stats
Open$5.32
Prev. Close$5.34
EPS-1.42
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$582.37M
PE Ratio-
LOWHIGH
Day Range5.14
5.41
52 Week Range0.77
9.39
Ratios
P/B Ratio4.89
Revenue$9.99M
Operating M. %3,149.63%
Earnings$0.00
Earnings Growth %-45.15%
EBITDA Margin %-645.79%
ROE %-682.16%
EPS-1.42

Score Breakdown

60vs 55. Market Avg.

All Score 60 / 100 is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

APLTMARKET
Value4240
Quality2740
Ownership3117
Growth9045
Dividends-38
check_circle

Applied Therapeutics Inc's Price growth average in the last 3 years of 122.46% is great compared to market average of 6.47%. This indicates APLT could be a good value stock.

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

info
Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$751.62
24H (%)arrow_drop_down1.04%
24H ($)-$7.97
MARKET CAP$724.46B
PRICE$438.91
24H (%)arrow_drop_down0.63%
24H ($)-$2.81
MARKET CAP$414.91B
PRICE$147.57
24H (%)arrow_drop_down0.81%
24H ($)-$1.21
MARKET CAP$361.94B
PRICE$126.33
24H (%)arrow_drop_up0.14%
24H ($)$0.18
MARKET CAP$321.01B

About Applied Therapeutics Inc (APLT)

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target central nervous system rare disease and diabetic complications in the United States. Its lead product candidate is AT-007 that has completed phase III for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Shoshana Shendelman Ph.D.
Headquarters
New York
Employees
22
Exchange
NASDAQ
add Applied Therapeutics Inc to watchlist

Keep an eye on Applied Therapeutics Inc

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Applied Therapeutics Inc (APLT) stock price performance year to date (YTD)?

As of the latest data, Applied Therapeutics Inc (APLT) has a year-to-date price change of 41.21%. Over the past month, the stock has experienced a price change of -15.88%. Over the last three months, the change has been 104.78%. Over the past six months, the figure is 112.4%.

help
What is Applied Therapeutics Inc's (APLT) price per share?

The current price per share for Applied Therapeutics Inc (APLT) is $5.14. The stock has seen a price change of -$0.2 recently, indicating a -3.75% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for Applied Therapeutics Inc (APLT)?

For Applied Therapeutics Inc (APLT), the 52-week high is $9.39, which is 82.68% from the current price. The 52-week low is $0.77, the current price is 566.67% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is Applied Therapeutics Inc (APLT) a growth stock?

Applied Therapeutics Inc (APLT) has shown an average price growth of 125.3% over the past three years. It has received a score of 96 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Applied Therapeutics Inc as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
Is Applied Therapeutics Inc (APLT) a profitable company?

Applied Therapeutics Inc (APLT) has a net income of -$119.76M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 3.15K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $9.99M, although specific revenue growth data is currently not available. The gross profit is $9.64M. Operating income is noted at -$64.54M. Furthermore, the EBITDA is -$64.53M.

help
What is the market capitalization of Applied Therapeutics Inc (APLT)?

Applied Therapeutics Inc (APLT) has a market capitalization of $582.38M. The average daily trading volume is 871.51K, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Approach investments with caution like a driver who slows down on a curvy road.